Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

Episode 3 – The Practicalities of Treatment

Gain valuable insights from leading healthcare professionals as they discuss what it means practically for the treating physicians, the multidisciplinary team and patients when going on treatment with radium-223 dichloride.

 

Speakers:

  • Dr YeePei Song - Consultant in Clinical Oncology
  • Dr Maryam Jessop - Chief Nuclear Medicine Technologist

 

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

This promotional podcast series has been initiated and funded by Bayer and is for healthcare professionals only.

XOFIGO▼ (radium-223 dichloride) Prescribing Information can be found here.

Reflective Learning Guide

Download Reflective Learning Guide

Speakers

Dr Yeepei Song

Dr Yeepei Song

 

Consultant in Clinical Oncology at The Christie Hospital.

 

Dr Song graduated from Queen’s University, Belfast in 2009 with a degree in medicine. She completed her general medical training in Northern Ireland prior to her clinical oncology training at The Christie Hospital and Rosemere Cancer Centre. Her research MD focused on the optimisation of radiotherapy in bladder cancers. She was awarded the Conquer Cancer Foundation Merit Award at the American Society of Clinical Oncology Genitourinary Cancers Symposium in 2019. In the same year, she was awarded a bursary from the Royal College of Radiologists to attend the ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research. She was appointed as a Consultant in Clinical Oncology at The Christie Hospital in 2020 and has a special interest in the treatment of bladder and prostate cancers. She also maintains a research and clinical trial interest in urological cancers.

Dr Maryam Jessop

Dr Maryam Jessop

 

Chief Nuclear Medicine Technologist at Brighton and Sussex University Hospitals.

 

Dr Jessop qualified in New Zealand in 1979, worked in Canada in the 1980's, then returned to New Zealand. Having worked in the UK since 1996, her current role is as Chief Nuclear Medicine Technologist and Advanced Practitioner in Molecular Radiotherapies at Brighton, who were among the first in the UK to offer a clinical Radium-223 dichloride therapy service. Dr Jessop has a keen interest in research, in addition to maintaining high professional and educational standards, with previous positions on the New Zealand Nuclear Medicine Training Board, Australian and New Zealand Society of Nuclear Medicine Accreditation Board, and is currently a CPD assessor and Equivalency assessor for the Institute of Physics and Engineering in Medicine.

Why treat with Xofigo?

Episode 1 - Why treat with Xofigo?

Optimising patient identification and referral

Episode 2 - Optimising patient identification and referral

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.

OPT-IN TO BAYER COMMUNICATIONS OPT-IN TO BAYER COMMUNICATIONS

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.

 

If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.